This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

In the middle of an otherwise celebratory paragraph sits a sentence that does two jobs. It admits that four patients have not yet reached the finish line. It also says the company expects them to get there. That sentence, from a filing by Immix Biopharma, Inc. (Nasdaq: IMMX), supplies the larger of the two numbers in the release’s headline. It is worth reading slowly.

What was reported

On September 29, 2026, Immix Biopharma said in a current report and an accompanying press release that its CAR-T cell therapy, NXC-201, has produced a complete response in 40 of the 45 patients enrolled in its Phase 2 NEXICART-2 trial. That is a rate of 89%, as assessed by an independent review committee. The trial is in relapsed or refractory AL amyloidosis. The company describes this as a disease in which the immune system keeps producing toxic light chains that clog the heart, kidneys and liver. It calls the update interim. Of the 25 newest patients, the company said 21 are in complete response and the remaining 4 are MRD-negative, meaning no residual disease was detected in the bone marrow. The filing says no relapses have been observed to date among patients who reached either state. It also says no neurotoxicity or enterocolitis has been observed to date, and that safety data through August 4, 2026 are generally consistent with earlier reports. The company describes itself as a global leader in this disease and says it plans a final readout and a biologics license application in mid-2027.

From a small trial to a larger argument

The story Immix is telling is about scale more than any single percentage. NEXICART-2 is fully enrolled, has what the company calls a registrational design, and now reports on its full 45 patients. That total includes the 25 new patients, which leaves 20 from the earlier readouts. The company’s president argued that the complete response rate has kept rising even as reported patient counts more than doubled. In early clinical data, that is the right argument to make. Small cohorts tend to flatter a therapy, and the test comes when the denominator grows. By the company’s account, the rate held up.

The chief executive framed the commercial logic in plain terms. Patients today face years of continuous treatment, and NXC-201 is pitched as a single treatment that could spare them that. The company also says the therapy has been awarded Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations. The company is pitching NXC-201 as a way to turn a chronic regimen into a one-time event, and this update is its bid to show the claim survives a bigger sample.

The sentence doing the heavy lifting

Now back to the four. The filing says that for those patients, bone marrow MRD-negativity predicts future complete response, “potentially increasing future CR rate up to 98%”. Each hedge in that phrase limits what is promised. Potentially means not yet. Future means not now. Up to sets a ceiling, not an expectation. The support offered is internal: to date, every patient in the trial who reached MRD-negativity went on to complete response within a year. That is a real pattern among the trial’s own patients. It is still a pattern and not a rule.

The arithmetic is simple enough to do in the margin. Forty in complete response plus four pending makes 44, which leaves one of the 45 patients in neither category. The portions of the release reviewed by this desk do not describe that patient.

What the release does not say

Three absences stand out. The first is follow-up. The phrase to date appears repeatedly, and a claim of no relapses to date is only as strong as the length of that period, which the documents do not state. The second is safety. The release names two side effects that have not been observed and calls the rest generally consistent with earlier data. It gives no figures for the other effects a CAR-T reader usually asks about first. The third is small and probably harmless. The filing and the release’s bullet points say mid-2027 for the final readout and application, while one sentence in the release body says only 2027. Shorthand, most likely, but a careful reader notices.

The paperwork contains something to admire, too. The press release is furnished under Item 7.01, which by its own boilerplate is not deemed filed. The core results, however, also appear under Item 8.01, which is filed. The company chose to put the numbers where they carry more formal weight.

Three ways this could go

If the four MRD-negative patients convert as the company expects, the final readout could lead with 44 of 45. The one-time-treatment pitch would then rest on something close to a clean sweep. If one or more does not convert, the counted 89% would still be the figure of record, and the company’s argument would shift toward durability rather than breadth. A third path is less comfortable. If longer follow-up surfaced relapses or a safety pattern not visible in data through August 4, 2026, the one-time framing would face its hardest test, because that framing depends on responses lasting. The signpost for all three is the same: whether the final readout reports how long patients have been followed and gives full safety tables alongside the response rate.

The desk’s view

To our eye, the counted number is the story, and it is a substantial one. It comes from an independent review committee, on a full enrollment, in a trial designed to support approval. The 98% is a company forecast built on a within-trial correlation. It is plausible, clearly labelled, and still a forecast. This desk’s reading is that the release is carefully drafted and that its hedges are honest ones. They are also load-bearing, and a reader who skims past them sees a bigger number than the trial has yet produced.

What to watch

  • Whether the four MRD-negative patients reach complete response, and when the company reports it.
  • The next safety update, extending the data beyond August 4, 2026.
  • The final NEXICART-2 readout and the biologics license application, both planned for mid-2027.

The first question this desk would put to Immix Biopharma is simple: how long, in months, has the median patient been followed? Until someone says, to date remains the most important phrase in the release.

Sources